Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Zulkiflu Musa Argungu

2 papers in the library · publishing 2025-2026

Papers

Efficacy of mindfulness-based cognitive therapy in mitigating depressive symptoms and suicidal ideation among institutionalized patients with major depressive disorder: findings from a randomized controlled trial.

European Archives of Psychiatry and Clinical Neuroscience June 12, 2026 Zulkiflu Musa Argungu, Ali Alhaiti, Ebtesam Abdulrahman Jibreel

An 8-week Mindfulness-Based Cognitive Therapy (MBCT) program added to standard pharmacological care reduced depressive symptoms and suicidal ideation more than standard care alone among 101 institutionalized patients with major depressive disorder in northern Nigeria. At the end of the 8-week intervention, MBCT patients scored an average of 9.4 points lower on the BDI-II depression scale and 5.7 points lower on the BSI suicidal ideation scale than controls. These improvements were still present at a 3-month follow-up, with large effect sizes. The findings suggest MBCT is a promising adjunct for institutionalized patients with MDD in this setting.

Evaluating the Efficacy of Mindfulness-Based Cognitive Therapy in Alleviating Depressive Symptoms, Reducing Rumination, and Preventing Relapse Among the Institutionalized Patients in Nigeria: A Randomized Controlled Trial.

The International journal of social psychiatry December 29, 2025 Zulkiflu Musa Argungu, Ali Alhaiti, Ebtesam Abdulrahman Jibreel

Mindfulness-based cognitive therapy (MBCT) reduced depressive symptoms and rumination in adults with recurrent depression, but it did not lower the risk of relapse. In a randomized trial with 101 patients who had three or more previous episodes, those who received eight weeks of group MBCT (including meditation, psychoeducation, and discussion) showed statistically significant reductions in depressive symptoms and rumination scores compared to a control group at a two-month follow-up. However, there was no significant difference between groups in depression relapse rates. MBCT appears helpful for symptom management but not for preventing relapse in this population.